SELENBP1 and nasopharyngeal carcinoma: In our study, 99 NPC patients were classified into 2 subgroups using the IHC SELENBP1 scores, SELENBP1 (+) subgroup (n = 26) and SELENBP1 (−) subgroup (n = 73), then we tried to analyze metastasis-free survival, recurrence-free survival, and OS rate of 2 subgroups.